Idarubicin hydrochloride is for intravenous infusion only and must never be given intramuscularly or subcutaneously. Administer slowly over 10 to 15 minutes into the tubing of a freely running intravenous infusion of 0.9% sodium chloride or 5% dextrose, preferably into a large vein to minimize the risk of extravasation and tissue necrosis. Prior to administration, flush the catheter to ensure patency. For adult induction therapy, the recommended dose is 12 mg/m2 daily for 3 days in combination with cytarabine. Dosage adjustments are required for renal impairment, with a 33% reduction if GFR is less than 30 mL/min or for patients on hemodialysis. For hepatic impairment, reduce the dose by 50% if bilirubin levels are 2.6 to 5 mg/dL and avoid use if bilirubin exceeds 5 mg/dL. Pediatric patients typically receive 10 to 12 mg/m2 IV daily for 3 days. Monitor cardiac, renal, and hepatic functions closely during therapy.

Details coming soon